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Abstract: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C 
virus (HCV) are the most prevalent deadly chronic viral diseases. HIV is treated by small 
molecule inhibitors. HBV is treated by immunomodulation and small molecule inhibitors. 
HCV is currently treated primarily by immunomodulation but many small molecules are in 
clinical development. Although HIV is a retrovirus, HBV is a double-stranded DNA virus, 
and  HCV  is  a  single-stranded  RNA  virus,  antiviral  drug  resistance  complicates  the 
development of drugs and the successful treatment of each of these viruses. Although their 
replication  cycles,  therapeutic  targets,  and  evolutionary  mechanisms  are  different,  the 
fundamental  approaches  to  identifying  and  characterizing  HIV,  HBV,  and  HCV  drug 
resistance are similar. This review describes the evolution of HIV, HBV, and HCV within 
individuals and populations and the genetic mechanisms associated with drug resistance to 
each of the antiviral drug classes used for their treatment. 
Keywords: HIV; HBV; HCV; antiviral therapy; drug resistance; evolution; quasispecies 
 
1. Introduction 
The human immunodeficiency virus (HIV), the hepatitis B virus (HBV), and the hepatitis C virus 
(HCV) each cause lifelong human infection and illness. HIV infects nearly 40 million persons and 
causes about two million deaths per year. HBV infects more than 400 million persons and causes 
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nearly one million deaths per year. HCV infects nearly 200 million persons and is responsible for 50 
to 75%  of  hepatocellular  carcinomas  in  industrialized  countries.  Antiviral  compounds  targeting 
essential enzymes and other viral targets are either licensed or in advanced clinical development for 
each of these infections. 
The development of drug resistance is the most compelling evidence that an antiviral drug acts by 
specifically inhibiting the virus rather than its cellular host. The genetic mechanisms of antiviral drug 
resistance  are  identified  during  the  earliest  stages  of  drug  development  by  in  vitro  selection 
experiments and by ex vivo analysis of viruses obtained from individuals receiving antiviral therapy. 
This review describes the evolution of HIV, HBV, and HCV within individuals and populations and 
the genetic mechanisms associated with drug resistance to each of the antiviral drug classes (Table 1). 
Table 1. Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis 
C Virus (HCV): Replication Characteristics and Antiviral Treatment. 
Virus 
Genomic 
Classification 
Intracellular 
Reservoir 
Mutation 
Rate* 
Plasma 
Levels† 
Recombination  Antiviral Drug Classes§ 
HIV  Retrovirus  Proviral DNA  10
−5  10
3 − 10
6 
Major contribution 
to virus evolution 
in individuals and 
populations 
Nucleoside RT inhibitors 
Nonnucleoside RT 
inhibitors 
Protease inhibitors 
Integrase inhibitors 
Fusion inhibitors 
CCR5 inhibitors 
HBV 
DS DNA 
virus with 
obligate RNA 
intermediate 
Nuclear 
covalently-
closed circular 
DNA 
(cccDNA)  
10
−5  10
5 − 10
9 
Possible 
contribution to 
virus evolution 
within individuals 
Interferon 
Nucleoside RT inhibitors 
HCV 
Positive 
single-
stranded RNA 
virus 
None  10
−4 − 10
−5  10
4 − 10
7 
Possible 
contribution to 
virus evolution 
within individuals 
Interferon + Ribavirin  
Protease inhibitors 
Nucleoside inhibitors  
Nonnucleoside inhibitors  
NS5A inhibitors  
Cyclophilin inhibitors 
*  Mutation  rates  during  a  single  round  of  replication  have  been  estimated  experimentally  for  
HIV-1.  For  HBV  and  HCV  these  rates  have  been  estimated  from  mathematical  models  and 
comparisons with other viruses.  
† RNA copies per  mL for HIV-1 and DNA copies per mL for HBV. Range encompasses the 
majority of untreated individuals with ongoing replication.  
§ HCV protease inhibitors are in Phase III clinical trials. HCV nucleoside, nonnucleoside, NS5A, 
and cyclophilin inhibitors are in Phase II clinical trials. 
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2. Viral Replication and Persistence 
2.1. HIV 
HIV enters CD4+ T lymphocytes in a three-step process: gp120 Env binds the CD4 receptor and 
induces a conformational change that enables it to also bind either the CCR5 or CXCR4 coreceptor. 
The  formation  of  the  gp120-CD4-coreceptor  complex  exposes  the  extended  form  of  the 
transmembrane gp41 protein, which fuses the virus and host cell membranes. Following cell entry and 
viral disassembly, HIV RT converts two copies of single-stranded RNA into minus-strand DNA and 
then copies minus-strand DNA to create a DS DNA copy of the viral genome. Integrase (IN) catalyzes 
the cleavage of conserved dinucleotides from the 3‘ ends of double-stranded HIV-1 DNA and remains 
bound to each of the 3‘-ends as this circular pre-integration complex translocates to the nucleus. IN 
then catalyzes the strand transfer reaction, which leads to the integration of the HIV-1 genome into the 
host genome. 
HIV integration is usually followed by viral transcription, translation, and maturation. The latter is 
characterized by the cleavage of Gag and Gag-Pol polypeptides by protease into the structural and 
enzymatic proteins of the newly created virus. However, in a certain proportion of infected cells, 
particularly in resting CD4+ T cells, HIV persists as an integrated proviral genome. Although many 
proviral DNA genomes are defective or irreversibly silenced by epigenetic mechanisms, many are also 
capable of reactivating particularly when the host cell undergoes immune stimulation. This proviral 
DNA reservoir decays slowly and is only minimally affected by antiretroviral therapy [1,2]. As a 
result, recurrent viremia and immunological decline ensue whenever therapy is discontinued regardless 
of the duration of previous virologic suppression. 
2.2. HBV 
In virions, the HBV genome is a relaxed circular DNA (RC-DNA) molecule that is only partially 
double stranded. After infection of a hepatocyte, RC-DNA is transported to the nucleus and converted 
by cellular enzymes into a covalently closed circular DNA molecule (cccDNA). cccDNA serves as the 
template  for  transcription  and  for  pre-genomic  RNA,  which  has  two  possible  fates:  (i)  it  can  be 
encapsidated with HBV viral polymerase, serve as the template for minus-strand DNA and RC-DNA, 
and secreted extracellularly or (ii) it can be recycled back to the nucleus to amplify or replenish the 
cccDNA pool [3]. 
HBV cccDNA is highly stable. It can be eliminated by cell turnover, immune  mechanisms, or 
possibly  epigenetic  silencing  [4–7].  Nonetheless,  most  acutely infected  adults  clear  their  infection 
within six months coincident  with the development of  antibodies  to the HBV  envelope  S protein 
(HBsAb  seroconversion)  and  the  disappearance  of  plasma  HBsAg  and  viral  DNA.  In  contrast, 
perinatally infected newborns, horizontally infected infants, and about 5 to 10% of immunocompetent 
adults develop persistent infection. Among individuals with persistent infection, spontaneous clearance 
is uncommon, occurring at a frequency of <1% per year [8]. 
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2.3. HCV 
HCV  is  a  positive-sense, single-stranded  enveloped virus  with  a  genome of  about  9.5 kb. The 
genome encodes a single large 9.0 kb open-reading frame flanked by conserved 5‘- and 3‘-untranslated 
regions.  The  5‘-untranslated  region  contains  the  internal  ribosomal  entry  site  (IRES),  which  is 
necessary  for  initiating  translation.  Viral  replication  occurs  in  a  membrane-associated  cytoplasmic 
replicase complex, consisting of the  nonstructural  proteins NS3, NS4A, NS4B,  NS5A, and  NS5B 
which directs the synthesis of a negative-strand copy of the genome. The resulting duplex RNA serves 
as a template for the synthesis of multiple copies of the positive-strand genome for protein production 
and packaging. 
HCV persists in up to 70% of untreated infected persons [9–11]. There is a strong association of 
HCV  clearance  with  genetic  variation  in  the  IL28B  gene  underscoring  the  importance  of  innate 
immunity in the host response to infection [12]. HCV‘s life-long persistence in the majority of infected 
persons in the absence of treatment is a remarkable demonstration of its ability to evade the innate and 
adaptive immune system of its host. The absence of a stable intracellular reservoir (in contrast to HIV 
and HBV), however, makes viral eradication possible. 
3. Virus Evolution in Individuals 
Viral evolution within an infected host is determined by the number of viral replication cycles, the 
frequency of nucleotide incorporation errors, the potential for viral recombination, and host-mediated 
and antiviral selection pressures. Intra-host viral genetic diversity also depends on the time between 
initial infection and viral sampling and on whether the initial infection was clonal or composed of 
multiple heterogeneous clones. 
Acute  HIV  infection  has  been  shown  to  be  clonal  in  the  majority  of  infected  patients  and 
oligoclonal in the remaining patients [13,14]. Such data, however, are not generally available for HBV 
and HCV. Transmitted HIV drug resistance also occurs commonly in many parts of the world but is 
extremely rare for HBV and HCV. 
Intra-host viral genetic diversity differs by genomic region with greater diversity occurring within 
genes  encoding  envelope  proteins  compared  with  structural  or  enzymatic  proteins.  Although 
synonymous  mutation  rates  are  usually  greater  than  nonsynonymous  mutation  rates,  synonymous 
mutations should not be assumed to be neutral because RNA viruses contain many functional genomic 
secondary  structural  elements  and  potentially  structural  constraints  imposed  by  viral  genome 
packaging [15,16]. 
HIV, HBV, and HCV are usually called quasispecies because they exist within individuals as highly 
heterogeneous virus populations that diversify during the course of infection. Although the extent of 
genomic diversity in these infections does not meet the original definition of a quasispecies, which 
requires  an  effectively  infinite  population  size,  population  geneticists  have  nonetheless  found 
quasispecies theory to be useful for finite viral populations with high mutation rates and have generally 
accepted the use of the term quasispecies when applied to HIV, HBV, and HCV infections [17,18]. 
   Viruses 2010, 2                         
 
 
2700 
3.1. HIV 
HIV, like most lentiviruses, replicates throughout the course of infection. Plasma virus RNA levels 
range from 10
3 to 10
6 copies/mL in most untreated infected individuals. The plasma virus half-life 
is estimated  to  be  about  five  hours  and  up  to  10
10  viruses  are  produced  each  day  in  untreated 
individuals [19]. 
Mutations occur at two stages of HIV replication: (i) when RT catalyzes the conversion of the two 
copies of single-stranded genomic RNA into DS DNA;  and (ii) when host DNA-dependent RNA 
polymerase transcribes viral RNA from provirus. HIV mutation rates per replication cycle have been 
estimated using intracellular fidelity assays designed to detect either the inactivation of a reporter gene 
or the reversion of an inactivating mutation in a reporter gene [20]. Based on such studies, the HIV-1 
nucleotide misincorporation rate has been estimated to be about 1 × 10
−5, which is similar to that of 
other retroviruses [21,22]. However, not all nucleotide positions mutate at the same rate. Mutations 
occur at increased rates in homopolymeric regions [23]. 
Recombination is a feature shared among retroviruses. It occurs because RT switches between two 
co-packaged SS RNA genomes as it creates a single DNA copy. If the co-packaged SS RNA genomes 
were derived during infection of a single cell by viruses with different sequences, then recombination 
during the next cycle of replication produces mosaic viral sequences that may differ from the parental 
genomes at multiple nucleotide positions [24,25]. Recombination, therefore, has a high potential to 
shape HIV evolution [26], although its effect is limited by the requirement that different HIV variants 
infect the same cell and by the possibility that the recombinant progeny may not replicate as well as 
their non-recombinant precursors [27,28]. 
HIV  is  under  constant  selection  pressure  to  avoid  adaptive  humoral  and  cellular  host  immune 
defenses, which results in a high frequency of mutation at HLA-compatible cytotoxic T lymphocyte 
(CTL) epitopes. In individuals infected with a single virus strain, genetic diversity usually increases 
progressively during the course of infection, by as much as 1% per year in the envelope gene [29]. In 
the absence of drug selection pressure, the rates of divergence are considerably lower in the enzymatic 
targets  of  therapy  [30,31].  However,  in  patients  receiving  incompletely  suppressive  antiretroviral 
therapy, many mutations can develop within days to weeks or months. 
APOBEC-mediated  deamination  of  cytidines  to  uracil  in  negative-strand  DNA  molecules  of 
retroviruses, retrotransposons, and hepatitis B is an innate host defense mechanism that results in a 
marked  excess  of  G-to-A  mutations  (GA  hypermutation)  in  viral  plus-strand  DNA  [32].  The 
antiretroviral effects of APOBEC3G (GGAG) and APOBEC3F (GAAA) are so significant that 
HIV is unable to replicate in the absence of Vif, a protein that neutralizes these enzymes. Although 
APOBEC-mediated  GA  hypermutation  of  HIV  usually  results  in  nonviable  viruses  relegated  to 
proviral DNA [33,34], the possibility that low-level APOBEC activity may have contributed to virus 
evolution is suggested by an increased frequency of nonsynonymous mutation at the dinucleotides 
typically targeted by APOBEC3G and APOBEC3F [35]. 
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3.2. HBV 
In the absence of therapy, plasma HBV DNA levels are often as high as 10
7 to 10
9 copies/mL and 
up to 10
11 to 10
13 virions per day may be produced within infected persons [36–38]. The half-life of 
HBV has been estimated to range from four hours for plasma viruses [39,40] to up to 24 hours for 
newly formed virions in the process of being released extracellularly [36,41]. 
HBV  mutations  accumulate  within  individuals  at  10
−4  to  10
−5  substitutions  per  nucleotide  per  
year [42–44]. On the basis of these data and comparisons with other hepadnaviruses, the mutation rate 
of HBV per round of replication is estimated to be about 10
−5, a rate similar to that of HIV and other 
retroviruses  [45,46].  Phylogenetic  analysis  of  complete  HBV  genome  sequences  suggests  that 
recombination  has  occurred  at  least  several  times  during  the  virus‘s  evolutionary  history  [47]. 
However the mechanism by which HBV recombination occurs and the frequency with which it leads 
to the development of new variants within individuals are not known. 
During acute infection, HBV faces selection pressure from the host‘s innate and adaptive immune 
systems [48,49]. However, once infection is established, HBV often evolves to induce an immune 
tolerant state that may benefit the virus by allowing those infected perinatally to survive to adulthood 
and to transmit their infection to future generations. 
Despite its high rate of mutation and replication, HBV‘s evolution is constrained because nearly 
two-thirds of its genome encodes multiple proteins in overlapping reading frames [50,51]. Therefore, 
regardless of the rate at which mutations occur, the rate at which they become fixed is lower than that 
for HIV and HCV. Drug resistance, in particular, evolves much more slowly for HBV than for HIV or 
HCV because even in the presence of antiviral therapy, drug-susceptible viruses remain capable of 
producing intracellular virus. NRTI-resistant viruses however are more successful at replenishing the 
cccDNA pool and at infecting new hepatocytes—the two steps that require reverse transcription of 
pre-genomic RNA [52]. 
The mean number of nucleotide differences between plasma virus clones within antiviral-naïve 
infected  persons  is  often  less  than  1%  in  the  core  and  polymerase  genes  particularly  during  the 
immunotolerant  stages  of  infection  [53–55].  However,  genetic  diversity  is  higher  during  antiviral 
treatment failure [55–57] and possibly during acute infection and those stages of infection in which the 
virus is under immune selection pressure. 
APOBEC mediated GA hypermutation manifests differently in HBV than in HIV. First, it is not 
caused solely by APOBEC3G and APOBEC3F. Additional APOBEC enzymes—including APOBEC3C, 
which has no dinucleotide preference—appear to contribute to hypermutation [58]. Second, HBV does 
not appear to have a defense mechanism (such as Vif) against GA hypermutation suggesting that 
APOBEC enzymes are not a critical threat to HBV replication. Third, hypermutated clones are detected 
at low levels (i.e., 0.1% to 5.0%) in most clinical plasma samples [55,59]. HBV GA hypermutation is 
important to recognize because certain drug-resistance mutations (A181T and M204I) are unlikely to be 
clinically significant if they occur in hypermutated, nonfunctional genomes [60]. 
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3.3. HCV 
HCV plasma levels typically range from 10
4.5 to 10
6.5 IU units/mL where one IU is about 1 to 5 
RNA copies depending on the commercial assay used for quantification [61]. HCV has an estimated 
half-life of about three hours and, in the absence of antiviral therapy, up to 10
12 virions are produced 
daily [62–65]. 
Like other RNA-dependent RNA polymerases (RdRp), HCV‘s polymerase has a high error rate. 
Studies of virus evolution during point source outbreaks and over short time spans have shown that 
HCV accumulates about 1 × 10
−3 nucleotide changes per site per year [66,67]. Based on these data and 
comparisons  with  related  viruses,  it  has  been  estimated  that  10
−4  to  10
−5  substitutions  occur  per 
nucleotide per round of replication [68], a mutation rate typical of non-retroviral RNA viruses. 
Recombination occurs through a process of template switching during replication in many families 
of positive-strand RNA viruses. However, intra-host recombination has rarely been observed [69] and 
there have only been several documented inter-genotypic or inter-subtype recombinants [70–72]. The 
paucity of recombination may reflect the lesser fitness of recombinants compared with their parental 
strains due to mutational incompatibilities. 
Adaptive humoral [73,74] and cellular [75,76] immunity create ongoing antiviral selection pressure 
throughout HCV infection. HCV also has multiple defense mechanisms against innate intracellular 
antiviral responses [77], but it is uncertain whether innate immunity influences HCV evolution within 
individuals. HCV‘s ability to respond to external selection pressure is demonstrated by the rapidity 
with which it can develop resistance to small molecule inhibitors in vitro and in vivo. 
HCV quasispecies become increasingly complex during the course of infection. On average, the 
genetic  distance  among  genomes  can  range  from  5  to  10%  in  NS5A  or  to  greater  than  10%  in 
hypervariable regions of the envelope [78–81]. 
4. Virus Evolution in Populations 
4.1. HIV 
HIV-1 and HIV-2 are two of more than 15 primate lentivirus species that differ from one other 
by 40 to 60% of their amino acids. HIV-1 groups M and N represent cross-species transmissions from 
chimpanzees,  whereas  groups  O  and  P  represent  cross-species  transmission  from  chimpanzees  or 
gorillas. HIV-1 group M is responsible for the worldwide HIV-1 pandemic; HIV-1 groups O, N, and P 
are extremely rare. Group M viruses began spreading among humans about 100 years ago and gave 
rise to multiple subtypes and well-characterized inter-subtype recombinants [82,83]. HIV-1 subtypes 
differ from each other by about 10 to 30% of their nucleotides throughout their genome. However, 
within  the  enzymatic  targets  of  therapy,  the  inter-subtype  diversity  averages  10  to  12%  at  the 
nucleotide level and 5 to 6% at the amino acid level (Figure 1). 
The NRTIs, INIs, and—to a lesser extent—the PIs are active against HIV-2 strains in vitro and 
in vivo and are likely to be active against the rare non-M HIV-1 groups. In contrast, the NNRTIs and 
the fusion inhibitor enfuvirtide appear to be consistently active only against group M viruses. CCR5 
inhibitors should theoretically be active against all HIV-1 strains that must bind the CCR5 receptor. 
There do not appear to be any consistent differences among group M subtypes in their susceptibility to Viruses 2010, 2                         
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the six antiretroviral drug classes [84]. However, there are several differences among the subtypes in 
their propensity to developing specific drug resistance mutations [85–95]. 
Figure  1.  Phylogenetic Trees Created from HIV-1 Group M RT, HBV RT, and  HCV 
Polymerase Sequences. The trees demonstrate the greater distances separating the HCV 
genotypes  compared  with  those  separating  the  HIV-1  group  M  subtypes  and  the 
HBV genotypes.  Distances  were  calculated  using  the  HKY85  substitution  model 
with rate variation conforming to a gamma distribution. Trees were constructed using the 
neighbor-joining algorithm. 
 
 
4.2. HBV 
HBV infects humans and non-human primates. There are at least eight HBV genotypes,  which 
differ from one other by approximately 8 to 10% of their nucleotides. However, because primate HBV 
sequences are very similar to non-primate HBV sequences, it is possible that multiple cross-species 
transmission events occurred and that current HBV strains in humans do not have a single common 
human virus ancestor (Figure 1). 
With the exception of genotype G viruses, which contain a 36-bp insertion in the core gene and two 
pre-core stop codons and which usually occurs in combination with genotype A viruses [96], there are Viruses 2010, 2                         
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no proven biological differences among the genotypes. Although several studies have suggested that 
the HBV genotype may influence disease progression and response to Interferon therapy, few data 
suggests that genotype influences viral response to NRTI therapy [97–101]. 
4.3. HCV 
There are six major genotypes that differ in their nucleotide sequence by 30% to 35%. Within 
genotypes, subtypes differ by 20% to 25% [102,103]. Although HCV shares the same basic genomic 
organization as other flaviviruses, they are only distantly related and the origin of HCV is uncertain 
(Figure  1).  Although  there  appear  to  be  no  differences  in  clinical  severity  among  the  various 
genotypes,  there  are  major  differences  in  the  response  to  IFN-based  therapy  [104–106].  Small 
molecule inhibitors have been targeted towards genotype 1 because this genotype is the most difficult 
to treat with IFN and Ribavirin and is the most prevalent genotype in the U.S. and Europe. 
5. HIV Drug Resistance 
Twenty-four antiretroviral drugs belonging to six mechanistic classes have been licensed for HIV-1 
treatment: Seven nucleoside and one nucleotide RT inhibitors (NRTIs), nine protease inhibitors (PIs), 
four non-nucleoside RT inhibitors (NNRTIs), one fusion inhibitor, one IN inhibitor (INI), and one 
CCR5  inhibitor.  In  previously  untreated  individuals  infected  with  drug  susceptible  HIV-1, 
combinations of three drugs from two drug classes leads to prolonged virus suppression and, in most 
patients,  immune reconstitution. Once  complete HIV-1 suppression is achieved,  it usually  persists 
indefinitely as long as therapy is not interrupted [107]. 
HIV-1 drug resistance may be acquired or transmitted. It is acquired in patients in whom ongoing 
virus replication occurs in the presence of suboptimal antiviral therapy. Although suboptimal antiviral 
therapy was once a consequence of an insufficient number of active drugs, it now usually results from 
treatment interruptions or incomplete adherence. Transmitted drug resistance accounts for about 15% 
of new infections in the U.S. [108], 10% in Europe [109], 5% in South and Central America, and less 
than 5% in most parts of Sub-Saharan Africa and South and Southeast Asia [110,111]. 
5.1. Nucleoside/Nucleotide RT Inhibitors (NRTIs) 
The NRTIs are prodrugs that must be triphosphorylated—or in the case of the nucleotide Tenofovir 
(TDF)  diphosphorylated—to  their  active  form.  This  dependence  on  intracellular  phosphorylation 
complicates the in vitro assessment of NRTI activity because phosphorylation occurs at different rates 
in  different  cell  types  and  leads  to  discordances  between  in  vitro  and  in  vivo  NRTI  potency. 
Specifically, differences in the intracellular dNTP pools between the highly activated lymphocytes 
used  for  susceptibility  testing  and  the  wider  variety  of  cells  that  are  infected  in  vivo  explain 
why NRTIs  differ  in  their  dynamic  susceptibility  ranges  and  in  their  clinically  significant  levels 
of in vitro  resistance  [112,113].  Clinical  isolates  from  persons  failing  NRTI  therapy  may  have 
several-hundred-fold  reductions  in  susceptibility  to  Zidovudine  (AZT),  Lamivudine  (3TC),  and 
Emtricitabine  (FTC),  but  will  rarely  have  more  than  five-fold  reductions  in  susceptibility  to Viruses 2010, 2                         
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Didanosine (ddI), Stavudine (d4T), and TDF. However, even slight reductions in in vitro susceptibility 
to this second category of drugs are clinically significant [114]. 
There  are  two  biochemical  mechanisms  of  NRTI  resistance  that  are  caused  predominantly  by 
mutations in the N-terminal polymerase-coding region of HIV-1 RT. One mechanism is mediated by 
discriminatory mutations that reduce the affinity of RT for an NRTI, preventing its addition to the 
DNA chain [115]. Another mechanism is mediated by ‗primer-unblocking‘ mutations that favor the 
hydrolytic removal of an NRTI that has been incorporated into the HIV-1 primer chain [112,116]. 
Because  they  are  selected  by  the  thymidine  analog  inhibitors  AZT  and  d4T,  primer-unblocking 
mutations are also referred to as thymidine analog mutations or ‗TAMs‘. 
All recommended first-line treatment regimens include one of the two cytosine analogues—3TC 
and FTC. Although highly potent, each has a low genetic barrier to resistance. A single mutation, 
M184V, confers a greater than 200-fold decrease in susceptibility to these drugs. Although M184V 
limits the effectiveness of 3TC and FTC for salvage therapy, both of these drugs retain some benefit 
even in the presence of this mutation—possibly as a result of the decreased replication capacity of 
viruses with M184V or of the fact that M184V increases HIV-1 susceptibility to AZT, d4T, and TDF, 
drugs that have frequently been used in combination with 3TC and FTC. 
The  most  common  TAMs  include  M41L,  D67N,  K70R,  L210W,  T215Y/F,  and  K219Q/E. 
A subset of  these  mutations—M41L,  L210W,  and  T215Y—is  particularly  important  for  causing 
cross-resistance to ddI, Abacavir (ABC), and TDF [117–119]. In patients receiving regimens without 
thymidine  analogs,  K65R  and  L74V  have  replaced  the  TAMs  as  the  mutations  that  occur  most 
commonly  in  combination  with  M184V.  K65R  causes  low-level  resistance  to  d4T,  intermediate 
resistance to 3TC and FTC, and high-level resistance to ABC, ddI, and TDF; however, it increases 
susceptibility to AZT [120,121]. 
T69SSS and Q151M are multi-NRTI resistance mutations. T69SSS is a double amino insertion at 
HIV-1 RT position 69. It nearly always occurs with multiple TAMs, where it causes intermediate 
resistance  to  3TC  and  FTC  and  high-level  resistance  to  the  remaining  NRTIs  [122,123].  Q151M 
usually occurs in combination with several otherwise uncommon mutations (A62V, V75I, F77L, and 
F116Y). It causes intermediate resistance to TDF, 3TC, and FTC, and high-level resistance to the 
remaining NRTIs [124,125]. 
Many additional accessory NRTI-resistance mutations have been described, including mutations in 
the C-terminal regions of HIV-1 RT [126–128]. Most of these C-terminal mutations appear to facilitate 
primer unblocking by slowing primer/template translocation or RNAseH activity [129,130]. A detailed 
review  of  the  role  of  C-terminal  mutations  in  HIV-1  RT  drug  resistance  is  also  included  in  this 
issue [131]. 
5.2. Nonnucleoside RT Inhibitor Resistance (NNRTIs) 
The  NNRTIs  inhibit  HIV-1  RT  allosterically  by  binding  to  a  hydrophobic  pocket  close  to 
the enzyme‘s  active  site.  This  binding  pocket  is  less  well  conserved  than  the  enzyme‘s  active 
dNTP-binding  site.  As  a  result,  group  M  viruses  have  greater  inter-isolate  variability  in  their 
susceptibility to NNRTIs than to NRTIs [132]. Three NNRTIs are commonly used: Nevirapine (NVP), 
Efavirenz (EFV), and Etravirine (ETR). Viruses 2010, 2                         
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Many single mutations in the NNRTI-binding pocket confer high-level NVP resistance; several also 
confer  high-level  EFV  resistance  (Table  2).  Resistance  emerges  rapidly  when  NNRTIs  are 
administered as monotherapy, or in the presence of incomplete virus suppression, which suggests that 
NNRTI resistance is caused by the selection of rare pre-existing populations of mutant viruses within 
an individual. The administration of a single dose of NPV to prevent mother-to-child HIV transmission 
routinely  selects  for  NNRTI-resistant  mutants  that  are  detectable  by  standard  sequencing  for  two 
months or longer [133,134]. 
A  minimum  of  two  mutations  is  required  to  cause  high-level  ETR  resistance  [135,136]. 
ETR‘s increased genetic barrier to resistance is a result of its ability to adopt multiple biding modes 
within the  NNRTI-binding  pocket  [137].  The  NRTIs  and  NNRTIs  are  often  synergistic.  Several 
NNRTI-resistance  mutations  increase  susceptibility  to  certain  NRTIs  [138]  and  several 
NRTI-resistance mutations increase NNRTI susceptibility [139,140]. 
5.3. Protease Inhibitors (PIs) 
More  than  80  non-polymorphic  PI-selected  mutations  have  been  reported  [127].  Most  of  these 
contribute to decreased in vitro susceptibility to one or more PIs [141,142]. The mutations with the 
greatest impact on susceptibility—D30N, V32I, G48V, I50V/L, V82A/T/L/F/S, and I84V/A—occur in 
the substrate  cleft  [142]  reducing the binding affinity  between  the PI  and  the protease. However, 
several mutations in the enzyme flap, such as I54M/L, and in the enzyme core, such as L76V, and 
N88S, can also markedly decrease PI susceptibility (Table 2). Mutations elsewhere in the enzyme 
either compensate for the decreased kinetics of enzymes with active site mutations; cause resistance by 
altering enzyme catalysis, dimer stability, and inhibitor binding kinetics; or by re-shaping the active 
site through long-range structural perturbations [143,144]. Mutations at several protease cleavage sites 
are also selected during PI treatment, improving the kinetics of protease enzymes with PI-resistance 
mutations [145–148].  
Ritonavir-boosted PIs, particularly lopinavir/r and darunavir/r have the highest genetic barrier to 
resistance among all antiretrovirals. Multiple mutations are required to compromise their antiretroviral 
activity [149–153]. 
5.4. Integrase Inhibitors (INIs) 
Although IN catalyzes both the 3‘-processing and strand-transfer reactions, only those compounds 
that specifically inhibit strand transfer are effective INIs [154,155]. The FDA-licensed INI raltegravir 
and two additional INIs in advanced clinical development—elvitegravir and S/GSK1349572—bind the 
essential divalent metal cations Mg
++ or Mn
++ and a hydrophobic region within a cavity formed by IN 
and the 3‘ HIV-1 DNA ends [156,157].  
Mutations  at  nine  positions  (T66I/A/K,  E92Q/V,  F121Y,  Y143C/R,  P145S,  Q146P,  S147G, 
Q148H/R/Q, and N155H/S) are selected by raltegravir or elvitegravir and reduce susceptibility to either 
one or both of these drugs by more than five-fold [158–163]. A large number of secondary compensatory 
mutations have also been described. The most important of these are G140S/A/C and E138K/A, which 
increase the fitness of viruses with Q148H/R/K and lead to high-level resistance to all INIs, and T97A, 
which causes high-level resistance to raltegravir in the presence of Y143C/R [163–166]. Viruses 2010, 2                         
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5.5. Fusion Inhibitors 
Enfuvirtide  is  a  synthetic  peptide  that  inhibits  fusion  by  binding  to  gp41‘s  HR1  region  and 
preventing it from folding back and binding to its HR2 region [167]. Enfuvirtide-resistant isolates 
contain either single or double mutations between positions 36 and 45 of gp41 HR1 [168,169]. Single 
mutants typically decrease enfuvirtide susceptibility about 10-fold whereas double mutations decrease 
susceptibility about 100-fold. Despite being one of the most potent antiretroviral drugs, the genetic 
barrier to enfuvirtide resistance is low and virological rebound emerges rapidly if Enfuvirtide is not 
administered with a sufficient number of other active inhibitors [170]. 
5.6. CCR5 Inhibitors 
Maraviroc  allosterically  inhibits  the  binding  of  HIV-1  gp120  to  the  seven-transmembrane  G 
protein-coupled  CCR5  receptor  [171].  CCR5  inhibitor  resistance  develops  during  in  vitro  passage 
experiments  via  gp120  mutations  that  enable  HIV-1  to  bind  to  the  CCR5—CCR5-inhibitor 
complex [172]. Resistance via this mechanism, however, does not occur rapidly nor does it occur by a 
consistent  pattern  of  gp120  mutations.  In  patients  receiving  CCR5  inhibitors,  the  most  common 
mechanism  of  virological  failure  is  the  expansion  of  pre-existing  CXCR4  tropic  viruses  that  are 
intrinsically insensitive to  CCR5 inhibitors  [173]. Less  commonly,  virological  failure  emerges  via 
mutations that allow the virus to bind to the CCR5—CCR5-inhibitor complex [174–176]. 
Table 2. Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitors. 
Drug Class 
Mechanism of 
Resistance 
Mutations  Drug Resistance Mutations 
Nucleoside/Nucleotide 
RT inhibitors 
(NRTIs):  
Abacavir (ABC)  
Didanosine (ddI) 
Emtricitabine (FTC) 
Lamivudine (3TC)  
Stavudine (d4T) 
Zidovudine (AZT) 
Tenofovir (TDF) 
RT mutations that 
enhance 
discrimination 
between NRTIs and 
natural nucleosides  
K65R, L74V, 
Y115F, Q151M, 
M184V 
K65R causes high-level resistance to ddI, 
ABC, and TDF, intermediate resistance to 
3TC and FTC, low-level resistance to d4T, 
and increased susceptibility to AZT. L74V 
decreases susceptibility to ddI and ABC. 
Y115F decreases susceptibility to ABC and 
TDF. Q151M causes high-level resistance to 
AZT, d4T, ddI, and ABC, and intermediate 
resistance to TDF, 3TC, and FTC. M184V 
causes high-level resistance to 3TC and FTC 
and low-level resistance to ABC and ddI. 
Reviewed in [177,178]. 
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Table 2. Cont.  
Drug Class 
Mechanism of 
Resistance 
Mutations  Drug Resistance Mutations 
 
RT mutations that 
promote ATP-
dependent 
hydrolytic removal 
of chain-terminating 
nucleotide 
monophosphates 
(also known as 
thymidine analog 
mutations or 
TAMs). 
M41L,  D67N, 
K70R,  L210W, 
T215F/Y, K219Q/E 
T69S_SS 
M41L, D67N, K70R, L210W, T215FY, and 
K219QE  develop  in  viruses  from  patients 
receiving AZT and d4T. The accumulation of 
several TAMs causes cross-resistance to each 
of  the  other  NRTIs  except  3TC  and  FTC. 
T69S_SS  is  an  uncommon  amino  acid 
insertion that confers resistance to each of the 
NRTIs  when  it  occurs  in  combination  with 
multiple TAMs. Reviewed in [177,178]. 
Non-nucleoside RT 
inhibitors (NNRTIs):  
Efavirenz (EFV) 
Etravirine (ETR) 
Nevirapine (NVP) 
Mutations in the 
HIV-1 RT NNRTI-
binding pocket  
L100I, K101E/P, 
K103N, V106A/M 
Y181C/I/V, Y188L 
G190A/S, M230L 
These mutations cause high-level resistance 
to NVP and intermediate or high-level 
resistance to EFV. With the exception of 
K103N, V106A/M, and Y188L, each 
mutation is also associated with decreased 
ETR susceptibility. Reviewed  
in [136,141,177]. 
Protease inhibitors 
(PIs): 
Atazanavir (ATV) 
Darunavir (DRV) 
Fosamprenavir (FPV) 
Indinavir (IDV) 
Lopinavir/r (LPV/r) 
Nelfinavir (NFV)  
Saquinavir (SQV) 
Tipranavir (TPV) 
Protease mutations 
interfere with 
inhibitor binding or 
compensate for the 
decreased 
replication 
associated with 
other mutations.  
D30N, V32I, 
V47V/A, G48V, 
I50V/L, 
I54M/L/V/A/T, 
L76V, 
V82A/T/F/S/L, 
I84V/A, N88S, 
L90M 
Positions 30, 32, 47, 48, 50, 82, and 84 are in 
the substrate cleft. Position 54 is in the flap 
and directly interacts with PIs as they enter 
the substrate cleft. The mutations at positions 
76, 88, and 90 influence the shape of the 
substrate cleft indirectly. Reviewed  
in [142,177]. 
 
These mutations are 
primarily 
compensatory 
L10I/V/F, L24I, 
L33F, M46I/L 
F53L, A71V/T/I/L, 
Q58E, G73S/T/C/A, 
T74P, N83D, 
N88D, L89V 
L10I/V, L33F, M46I/L, and A71V/T are 
minimally polymorphic occurring in 0.5% to 
5% of viruses from untreated persons 
depending on the subtype. Reviewed  
in [142,177]. 
Integrase inhibitors 
(INIs): 
Raltegravir (RAL) 
In Phase III trials: 
Elvitegravir (EVG) 
S/GSK1349572 (572)  
Mutations in 
residues 
surrounding the IN 
active site. 
Q148H/R/K ± 
G140SA, N155H ± 
E92Q, Y143C/R,  
T66I/A/K, S147G 
Q148H/R/K ± G140SA cause high-level 
RAL and EVG resistance and intermediate 
572 resistance. N155H + E92Q causes high-
level RAL and EVG resistance. Y143C/R + 
T97A causes high-level RAL resistance. 
T66I and S147G are selected in patients 
receiving EVG and decrease EVG 
susceptibility but do not appear to cause RAL 
cross-resistance. Reviewed in [179]. Viruses 2010, 2                         
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Table 2. Cont.  
Drug Class 
Mechanism of 
Resistance 
Mutations  Drug Resistance Mutations 
Fusion inhibitors: 
Enfuvirtide (ENF) 
Mutations in the 
first heptad repeat 
region (HR1) of the 
gp41 
transmembrane 
protein interfere 
with the association 
of HR1 and HR2 
required for virus 
cell fusion. 
G36D/E/V/S, I37V, 
V38E/A/M/G, 
Q48H, N42T, 
N43D/K/S, L44M, 
L45M  
G36D/E, V38E/A, Q40H, and N43D each 
reduce ENF susceptibility >10-fold  
[168,169]. Two mutations are usually 
sufficient to cause high-level ENF resistance.  
CCR5 inhibitors: 
Maraviroc (MVC) 
Virological failure 
and resistance is 
usually caused by 
expansion of pre-
existing CXCR4-
tropic variants that 
were not detected at 
the start of therapy. 
In vitro, and 
occasionally, in vivo 
resistance is caused 
by gp120 mutations 
that facilitate 
binding to an 
inhibitor bound 
CCR5 molecule. 
Positively charged residues at positions 11 and 25 of the V3 loop of 
gp120 and many other combinations of mutations primarily but not 
exclusively within the V3 loop are associated with CXCR4 tropism 
[180]. No consistent pattern of gp120 mutations has been identified 
to be associated with virus binding to an inhibitor-bound CCR5 
receptor [174–176]. 
 
6. HBV Drug Resistance 
There are two forms of Interferon and five nucleoside/nucleotide analogs (NRTIs) licensed for the 
treatment of chronic HBV infection. Alpha IFN was licensed in 1992 and pegylated alpha IFN 2a was 
licensed in 2005. The five NRTIs are 3TC (1998), Adefovir (ADV; 2002), Entecavir (ETV; 2005), 
Telbivudine (LdT; 2006), and TDF (2008). FTC, which is structurally similar to 3TC, is also active 
against HBV and is frequently used for HBV treatment because it is co-formulated with TDF to treat 
HIV. 3TC, FTC, and LdT are L-nucleoside analogs; ADV and TDF are acylic nucleotide analogs; and 
ETV is a deoxyguanosine analog. 
3TC, FTC, ADV, and TDF were each originally identified as antiretroviral drugs used for HIV-1. 
ETV, which was originally reported to be inactive against HIV-1 in vitro, was subsequently shown to 
reduce plasma HIV-1 RNA levels and to select for the RT mutation M184V in HIV-1 co-infected 
patients [100]. 
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6.1. Interferon (IFN) 
Although NRTIs are used more commonly than -IFN, pegylated -IFN is an important option for 
HBV treatment because unlike the NRTIs, a 24 to 48 week course of therapy is associated with an 
increased  likelihood  of  sustained  virologic  response  and  HBsAb
+/HBsAg
−  seroconversion.  Recent 
pilot studies  have  also  suggested  that  a  combination  of  NRTIs  plus  pegylated  -IFN  may  induce 
higher rates  of  sustained  response  and  HBsAb
+/HBsAg
-  seroconversion  than  pegylated  -IFN 
alone [181–184]. 
6.2. Nucleoside/Nucleotide RT Inhibitors (NRTIs) 
The three-dimensional structure of HBV RT has not been solved because it has been difficult to 
obtain sufficient amounts of highly purified active protein. However, homology modeling with other 
polymerases, including HIV-1 RT, has shown that HBV RT contains regions similar to the fingers, 
palm,  and  thumb  of  HIV-1  and  seven  sub-domains  that  are  conserved  among  many  published 
polymerase enzyme sequences [185,186]. In 2001, a standardized numbering system for mutations was 
established for the RT part of the HBV pol gene [187]. 
3TC resistance during 3TC monotherapy develops in 15% to 30% of individuals treated for one 
year,  40%  to  50%  treated  for  three  years,  and  70%  treated  for  five  years  [188–190].  High-level 
(>1,000 fold) 3TC resistance is caused by the mutations M204V/I, which are in the YMDD motif 
adjacent  to  two  of  the  RT  enzyme‘s  catalytic  aspartates  [191,192]  and  likely  sterically  inhibits 
HBV RT binding to 3TC [185]. M204 mutations are also frequently accompanied by compensatory 
mutations, particularly L180M and, less commonly, V173L and/or L80V/I [192–195] (Table 3). M204 
mutations are also selected by LdT, albeit at a slower rate than 3TC: 11% versus 26% after two years 
of monotherapy [196]. 
Although both HIV-1 and HBV develop 3TC resistance by the substitution of an I or V for an M in 
their RT‘s YMDD motif, the slower development of HBV resistance and HBV‘s frequent requirement 
for compensatory mutations in addition to M204V/I contrasts with the rapid development of 3TC 
resistance by M184V/I alone in HIV-1-infection. 
High-level ETV resistance requires M204V/I + L180M and two or three of the following additional 
mutations I169T, T184S/A/G, S202G/I, or M250V [197–201]. Virological failure and ETV resistance 
are exceedingly uncommon when ETV is used to treat NRTI-naïve patients [200]. Although ETV 
retains considerable antiviral activity against 3TC-resistant variants [199,202], the risk of virological 
failure and high-level ETV resistance is considerable in 3TC-resistant patients. 
ADV resistance emerges more slowly than 3TC resistance. It occurs in about 10% and 30% of 
individuals receiving ADV monotherapy for two and five years, respectively [189,203–205]. N236T 
and A181V/T, mutations close to the HBV active site, reduce ADV susceptibility by about 3 to 10-fold 
[204,206–209]. Although these  reductions  in  susceptibility are  much  lower than the level of 3TC 
resistance conferred by M204V/I, they are associated with virologic breakthrough [206,207]. N236T 
causes partial cross-resistance to TDF but not to 3TC, LdT, or ETV [210]. 
ADV and TDF retain complete antiviral activity in vitro against viruses with the 3TC-resistance 
mutations:  M204V/I,  L180M,  V173L,  and  L80I/V  [208,211–213].  Indeed,  these  mutations  may Viruses 2010, 2                         
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increase HBV susceptibility to ADV and TDF [214–217]. TDF has a high genetic barrier to resistance 
and the emergence of virological failure and TDF resistance is exceedingly uncommon when TDF is 
used to treat NRTI-naïve patients. 
The HBV RT mutations A181V/T are unique in that they confer resistance to both L-nucleosides 
and  acyclic  nucleoside  phosphonates  and  have  emerged  in  individuals  receiving  ADV  and,  less 
commonly, 3TC [208,218–221]. A181T is of particular interest because it causes a stop codon in the 
reading  frame  coding  for  the  surface  protein,  potentially  allowing  for  ongoing  hepatocellular 
replication without accompanying viral load rebound [222]. N236T, and to a lesser extent, A181V/T 
confer partial cross-resistance to TDF [223–225] and ETV is recommended for patients with these 
mutations [216]. 
Table 3. Mechanisms of Resistance to Hepatitis B Virus (HBV) Inhibitors. 
Antiviral Agents  Mechanism of resistance  Mutations  Drug Resistance 
Interferon  Unknown  Unknown  Unknown 
Lamivudine 
(3TC) 
Telbivudine 
(LdT) 
Emtricitabine 
(FTC)
* 
Entecavir (ETV) 
Adefovir (ADV)  
Tenofovir (TDF) 
RT mutations that 
interfere with nucleotide 
triphosphate binding. 
Whether any of these 
mutations also facilitate 
primer unblocking is not 
known. 
M204V/I  
L180M  L80I, 
V173L 
M204V/I  L180M and less commonly L80I 
and V173L emerge during 3TC treatment and 
confer cross-resistance to LdT and FTC; and 
partial cross-resistance to ETV. M204V/I also 
emerge during LdT therapy. Reviewed in 
[215,223,226]. 
N236T  Selected  by  ADV  and  causes  partial  cross-
resistance to TDF. Reviewed in [215,223,226]. 
A181V/T  Selected  by  ADV  and  less  commonly  3TC. 
May causes partial cross-resistance to TDF but 
not ETV. Reviewed in [215,223,226]. 
I169T, 
T184S/A/G,  
S202G/I, M250V 
Selected  by  ETV  particularly  in  viruses  with 
pre-existing  3TC-resistance  mutations. 
Reviewed in [215,223,226]. 
* FTC is not licensed for HBV treatment. However, it is frequently used in combination with 
Tenofovir for salvage therapy because there is a co-formulated version of TDF and FTC (Truvada) 
licensed  for  the  treatment  of  HIV-1.  Several  mutations  are  not  shown  because  they  are  either 
extremely rare (e.g., M204S, A181S) or because their association with resistance is controversial: 
e.g., A233V for Adefovir [227–229], and A194T for Tenofovir [230–231]. 
 
7. HCV Drug Resistance 
Although the combination of Peginterferon- and Ribavirin is currently the only licensed treatment 
for  HCV  [106],  many  HCV-specific  inhibitors  are  in  advanced  clinical  development.  Two  PIs, 
telaprevir (TVR, formerly VX-950) and boceprevir (BVR, formerly SCH-503034) are in Phase III 
trials and at least 20 additional compounds—PIs, nucleoside inhibitors (NIs), nonnucleoside inhibitors 
(NNIs), an NS5A inhibitor, and a cyclophilin inhibitor—are in Phase II trials [232–235]. Improved 
in vitro systems that support intra-cellular replication have been essential to identifying HCV inhibitors 
and the genetic mechanisms of antiviral drug resistance [236–239]. 
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7.1. Interferon (IFN) and Ribavirin 
Pegylated -IFN plus Ribavirin for six to 12 months is the standard treatment for HCV. Viral 
factors as well as host factors influence the response to IFN therapy. First, HCV genotype 2 and 3 
viruses are significantly more likely than genotype 1 viruses to respond to IFN (sustained virologic 
response rates are about 70% for types 2 and 3 versus 45% for type 1) [105,106,240,241]. Second, 
therapy  is  more  successful  in  acutely  infected  persons  possibly  because  they  harbor  less-complex 
mixtures of quasispecies than do chronically infected persons  [242,243]. Indeed, the likelihood of 
response to IFN is usually inversely proportional to the complexity of its quasispecies  [244–248]. 
Third,  specific  mutational  patterns  in  a  40-amino-acid  region  of  genotype  1b  NS5A  have  been 
associated with IFN responsiveness in several studies [249–251]. However, no specific mutations have 
been shown to be selected by or cause resistance to either IFN or Ribavirin [252–254]. 
A dose-response relationship exists between the nucleoside analog ribarivin and the likelihood of 
virologic  suppression.  Ribavirin  interferes  with  dNTP  metabolism  by  inhibiting  cellular  inosine 
monophosphate dehydrogenase [255,256] but may also directly inhibit HCV RNA polymerase [257], 
increase HCV mutagenesis [258,259], or modulate the HCV T cell immune response [256]. 
7.2. Protease Inhibitors (PIs) 
The  NS3  serine  protease  comprises  the  189  N-terminal  amino  acids  of  NS3.  NS3  forms  a 
heterodimer with the 54-amino-acid NS4A cofactor. The HCV protease cleaves four sites in the HCV 
polypeptide precursor to generate the N termini of NS4A, NS4B, NS5A, and NS5B. Typical of other 
members of the trypsin family of serine proteases, NS3/4A contains a catalytic triad composed by H57, 
D81, and S139. Multiple three-dimensional structures of NS3/4A with and without inhibitors have 
been determined [260]. 
The HCV protease is a challenging drug target because it has a shallow substrate-binding pocket 
that normally binds a long peptide substrate with which it forms multiple weak interactions [261]. 
Sequence analysis of individual cleavage sites indicates that the intermolecular consensus sequence is 
relatively  non-conserved:  D/E-X-X-X-X-C/TA/S-X-X-X  where  X  indicates  multiple  allowable 
residues [261,262]. Most HCV PI-resistance mutations occur within or near the substrate binding cleft 
particularly in the P1 to P4 binding pockets (S1 to S4 subsites; Figure 2). PI-resistance mutations 
selected in vitro have generally been predictive of those mutations selected in vivo [263]. 
The PIs, TVR and BVR are linear peptidomimetics that bind covalently but reversibly to the active 
site  serine.  When  combined  with  -IFN  plus  ribavirin,  TVR  and  BVR  increase  the  frequency  of 
sustained virologic response by about 25% compared with placebo [264–267]. 
PI resistance occurs commonly in those patients who do not achieve a sustained virologic response. 
The  protease  mutations  associated  with  resistance  to  TVR  and  BVR  are  nearly  completely 
overlapping.  They  include  V36A/M/L/C,  T54A/S,  R155K/T,  A156S/V/T,  and  V170A  (Table  4) 
[233,263,268–270].  The  emergence  of  two  PI-resistance  mutations  is  generally  sufficient  for 
high-level  resistance  and  virological  failure.  Several  macrocyclic  PIs  including  TMC435  [271], 
vaniprevir (formerly MK-7009) [272], and danoprevir (formerly ITMN-191 and R7227) [273] that do 
not covalently bind the active site serine are also in Phase II clinical trials. In vitro selection and drug Viruses 2010, 2                         
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susceptibility studies show that Q41R, F43S, R155K/T, A156S/V/T, and D168A/E/H/T/V/Y are the 
most important mutations for these inhibitors. 
Although  the  mutations  associated  with  HCV  PI  resistance  are  for  the  most  part  conserved  in 
genotype 1 viruses, sporadic mutations at these positions have been reported both as majority variants 
detectable  by  standard  sequencing  and  as  minority  variants  detected  by  deep  sequencing 
methods [274,275]. In two studies of HCV protease sequences from more than 1,000 individuals with 
genotype I viruses, R155K was found in 0.7% of patients and V36M, T54A, D168E, and V170A were 
found in about 0.5% of patients [274,275]. Specific genotype-associated variants occur at accessory 
PI-resistance positions [276] and current PIs may have considerably decreased activity against viruses 
belonging to non-genotype 1 viruses [233]. 
Figure 2. HCV NS3 Protease Variability and Protease Inhibitor (PI) Resistance Mutations. 
Alignment of NS3 residues 36 to 170 showing: (i) The consensus genotype 1a sequence 
and  common  variants  in  genotype  1  (GT1)  and  genotypes  2  to  6  (GT2–6)  according 
to [277]; (ii) The active site residues are shaded blue-grey; (iii) The substrate binding site 
positions  are  shaded  grey.  The  subsite  numbering  was  derived  from  the  following 
references:  [278–282];  (iv)  Mutations  selected  by  specific  PIs  and/or  associated  with 
decreased PI susceptibility are indicated beneath the alignment. Underlined positions have 
been  reported  to  decrease  susceptibility  >10-fold.  PI  abbreviations:  Telaprevir  (TVR), 
boceprevir  (BVR),  danoprevir  (R7227),  and  vaniprevir  (MK-7009).  TMC435  does  not 
have a generic name. 
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7.3. Nucleoside (NI) and Non-nucleoside (NNI) Inhibitors 
HCV  RdRp  is  encoded  by  the  530  N-terminal  amino  acids  of  the  NS5B  gene.  A  C-terminal 
extension of NS5B anchors the catalytic domain to the endoplasmic reticulum as part of a larger viral 
replication complex that includes the NS3 RNA helicase. HCV RdRp, like other polymerases, contains 
palm, thumb, and finger subdomains that enclose the RNA template groove and a GDD catalytic 
triad [260].  HCV  RdRp  inhibitors  include  chain-terminating  nucleoside  analogs  (NIs)  and 
non-nucleoside analogs (NNIs) that target NS5B allosterically. Most HCV NIs differ from HIV-1 and 
HBV  NRTIs  in  that  chain  termination  is  caused  by  steric  hindrance  rather  than  the  absence  of  
the 3‘-hydroxyl group [68]. 
In contrast to the HCV PIs, NIs appear to be active against each of the HCV genotypes. The genetic 
barrier to NI resistance is higher than for the PIs and NNIs with prolonged in vitro passage required for 
the emergence of resistance [283]. Furthermore, the mutations associated with NI resistance generally 
reduce  viral  fitness  to  a  greater  extent  than  the  NNIs  and  PIs  [284,285].  Two  non-cross-resistant 
mutational  patterns  associated  with  NI  resistance  have  been  described  (Table  4):  the  active  site 
mutation S282T has  been  selected  in  vitro by 2‘-C-methyl  modified  nucleoside analogs including 
valopcitabine  (NM203,  an  oral  prodrug  of  the  nucleoside  analog  2‘-C-methylcytidine),  R7128  
(a pro-drug of PSI-6130), and MK-0608 (2‘-C-methyl-7-deaza-adenosine) [284,286]. S282T appears 
to sterically inhibit NIs containing 2-methyl-substituded nucleoside analogs [287]. S96T  N142T, 
which  are  far  from  the  active  site,  are  selected  in  vitro  by  R1626  (a  prodrug  of  R1479, 
4‘-azidocytidine) [288]. 
In a Phase II trial, the combination of R1626, Peginterferon alfa-2a, and Ribavirin led to complete 
virologic suppression by week four in nearly 75% of patients without selecting for S96T  N142T, the 
R1626-resistance mutations  [289]. In another dose-finding study of 32 patients  receiving RG7128 
monotherapy for two weeks and 85 patients receiving RG7128 for one month, the vast majority of 
patients experienced continuous virus load decline proportional to the RG7128 dose without evidence 
for the emergence of S282T, the R7128-resistance mutation. Similarly, in a dose-ranging study of  
MK-0608  administered  intravenously  and  orally  to  chimpanzees  for  37  days,  plasma  HCV  levels 
displayed marked reductions in plasma HCV levels with the development of minority populations of 
S282T in two chimpanzees. 
Although R1626 and valopcitabine have been withdrawn because of toxicity  [232], the limited 
clinical experience with R1626 and the ongoing studies with RG7128 and MK-0608 demonstrates the 
potential  of  the  HCV  RdRp  NI  class.  The  absence  of  significant  in  vivo  resistance  to  HCV  NIs 
contrasts with the frequent resistance to the NRTIs used in the treatment of HIV and HBV. In a recent 
two-week clinical trial of the RG7128 in combination with the PI danoprevir (INFORM-1), subjects 
experienced a 3.7 to 5.2 log10 decrease in HCV IU/mL. Not only did RG7128 mutations fail to emerge, 
the combination also appeared to prevent the emergence of resistance to the PI danoprevir over the two 
week trial period [290]. 
Investigational non-nucleoside inhibitors (NNIs) targeting four allosteric binding sites are in early 
clinical development [232,291–293]. Two of these sites are in the thumb subdomain and two are in the 
palm subdomain. Mutations associated with resistance to each of the four allosteric sites have been 
selected in vitro and/or in vivo [233] (Table 4). Cross-resistance between NNIs and NIs has not been Viruses 2010, 2                         
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described. However, NNIs have uniformly displayed a low genetic barrier to resistance [294–296] and 
the activity of NNIs has often been variable even within the same genotype [295,297]. Moreover, 
several NNI- resistance mutations have been identified in previously untreated individuals either as 
dominant variants detected by standard sequencing or as minor variants detected by more sensitive 
methods [275,297,298]. 
7.4. NS5A Inhibitors 
NS5A is a 447 amino acid membrane-associated phosphoprotein that is an essential part of the HCV 
replicase complex and an antagonist of endogenous IFN. The structure of the N-terminal domain of 
NS5A  has  been  crystallized  but  how  this  domain  and  the  complete  protein  functions  are  not 
known [299,300]. BMS-790052 was identified by a high throughput screening approach for targeting 
non-enzymatic HCV targets. It has an EC50 of below 10 picomoles in genotype 1a and 1b replicons. It 
decreased HCV plasma RNA levels about 1,000 fold within 24 hours in a randomized, double-blind, 
single ascending dose study [235]. 
The specificity of BMS-790052 for NS5A was demonstrated by the selection of mutations in the 
N-terminal domain that conferred high-level BMS-790052 resistance [235,301,302]. A combination of 
two BMS-790052 mutations is required to cause high-level BMS-790052 resistance [302]. 
7.5. Cyclophilin Inhibitors 
Cyclophilin  A  is  an  important  cellular  cofactor  for  HCV  replication.  Although  the  role  of 
cyclophilin A in HCV replication is not known, it appears to a binding partner of NS5A and possibly 
other HCV proteins [303]. Debio 025 is a non-immunosuppressive cyclosporine analog that potently 
inhibits the interaction of cyclophilin A and HCV in vitro [303] and in vivo [304]. The genetic barrier 
to Debio 025 resistance is high [305] and may require the selection of cyclophilin A-independent 
NS5A  variants  [303].  Drugs  that  block  the  interaction  of  cyclophilin  A  with  HCV  are  somewhat 
analogous to HIV CCR5 inhibitors in that the primary target of therapy is a host protein. 
Table 4. Mechanisms of resistance to Hepatitis C Virus (HCV) inhibitors. 
Antiviral 
Agents 
Mechanism of 
resistance 
Mutations  Drug Resistance 
Interferon-  Unknown     Genotype 1 isolates respond less well than genotype 2 or 
3 viruses but the molecular basis is not known.  
Ribavirin  Unknown    Unknown 
PIs: 
Telaprevir 
(TVR) 
Boceprevir 
(BVR) 
TMC435  
Danoprevir 
Vaniprevir  
Mutations 
within  or  near 
the  protease 
substrate cleft 
V36A/M/C, Q41R, 
F43S/I/V, T54A/S, 
Q80K/R, R155K/T, 
A156S/V/T, 
D168A/E/I/N/T/V/Y, 
V170A/T 
R155K/T and A156S/V/T decrease susceptibility to all 
PIs. V36A/M/C and T54A/S decrease susceptibility to the 
linear peptidomimetics TVR and BVR. V170A is selected 
by BVR but may cause cross-resistance to TVR. Q41R, 
F43S/I/V, and D168 mutations decrease susceptibility to 
TMC435, danoprevir, and vaniprevir. Q80K, a common 
polymorphism in genotype 1a, and V170T decrease 
TMC435 susceptibility about  
5-fold.[233,263,268,271,272] Viruses 2010, 2                         
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Table 4. Cont. 
Antiviral 
Agents 
Mechanism of 
resistance 
Mutations  Drug Resistance 
NIs: 
NM203 
(withdrawn) 
R1626 
(withdrawn) 
R7128  
MK-0608 
Steric 
hindrance  of 
nucleoside 
analog 
incorporation 
(S282T) 
S282T  S282T in combination with compensatory mutations has 
been  selected  in  vitro  by  2‘-C-methyl  modified  NIs 
including valopcitabine (NM203, an oral prodrug of the 
nucleoside  analog  2‘-C-methylcytidine)  and  R7128  (a 
pro-drug of PSI-6130).  
S96T  N142T  S96T  N142T are selected in vitro by R1626 (a prodrug 
of R1479, 4‘-azidocytidine). These mutations are far from 
the  HCV  polymerase  active  site.  R1626  has  been 
withdrawn from clinical development [288]. 
NNIs  Decreased 
binding to NNI 
I pocket (upper 
thumb) 
P495S/A/L, 
P496S/A, V499A  
NNI site 1 is about 30Å from the active site [306]. A 
series of benzimidazole 5-carboxamide compounds bind 
to this site [292,307,308]. GS9190, BI207127, and 
MK3281 are site 1 NNIs in clinical development 
[68,233]. Mutations at positions 495, 496, and 497 reduce 
susceptibility to site 1 NNIs [68,233]. 
Decreased 
binding to NNI 
site 2 (base of 
thumb) 
L419V/M, 
M423T/V/I, 
I482L/V/T, V494A/I  
NNI site 2 is a shallow hydrophobic pocket at the base of 
the thumb close to NNI site 1 and ~35Å from the active 
site. Compounds that bind to this site such as filibuvir, 
VC-759, and VCH-796 have selected the mutations 
L419M, M423T/V/I, I482L, and V194A 
[68,233,294,309].  
Decreased 
binding to NNI 
site  3  (inner 
thumb / palm) 
H95R, M414T, 
C451R, G554D, 
G558R, D559G  
Benzothiadizine compounds that bind to this site have 
selected for M414T, C451R and G558R [310]. ANA598 
is a site 3 NNI in Phase II trials [233]. Mutations 
associated with this drug have include M414T, G554D, 
and D559G [233]. M414T, which is polymorphic in 
genotypic 1 viruses, may play a role in resistance to both 
site 3 and site 4 NNIs. 
Decreased 
binding to NNI 
site 4 (palm) 
C316N/Y, S365T, 
L392F, M414T, 
Y448H  
C316Y is selected rapidly in vitro by HCV-796 [311], a 
site 4 NNI that is no longer in clinical development. Other 
mutations that have been selected by HCV-796 include 
C316N, S365T/A, L392F, and M414T [233,311]. ABT-
333 is a site 4 NNI that has selected for C316N/Y and 
Y448H [233]. 
NS5A 
inhibitors: 
BMS-790052 
Unknown  M28T, Q30E/H/R, 
L31M/F/V, P32L, 
Y93C/H/N 
In selection experiments with BMS-790052, M28T, 
Q30E/H/R, L31M/V, P32L, and Y93C/H/N have been 
selected in a genotype 1a replicon. L31F/V, P32L, and 
Y93H/N have been selected in vitro in a genotype 1b 
replicon. Two mutations are usually required for high-
level resistance [302]. 
Cyclophilin 
inhibitors: 
Debio 025 
Unknown  Unknown 
* All compounds other than IFN and Ribavirin are in clinical development. 
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8. Conclusions 
Nearly 25 drugs belonging to six drug classes have been licensed for treating HIV-1. In previously 
untreated individuals infected with drug susceptible HIV-1, combinations of three drugs from two drug 
classes leads to prolonged virus suppression. However, because HIV cannot be eradicated from its 
proviral DNA reservoir lifelong therapy is necessary. Prolonged therapy carries the risk that periods of 
nonadherence will lead to the selection of drug-resistance variants. This risk is particularly high in 
low-income countries where interruptions in drug supply occur, the regimens used have lower genetic 
barriers  to  resistance  than  those  used  in  high-income  countries,  and  laboratory  monitoring  is  less 
intensive. Continued research is therefore required to develop fixed-dose drug combinations with high 
genetic barriers to resistance that can be administered safely for long periods of time. 
Although the fewest therapeutic options are available for treating HBV, it is the only virus in this 
review  for  which  monotherapy—with  either  ETV  or  TDF—is  capable  of  fully  suppressing  virus 
replication for many years in previously untreated persons. HBV has generally not been considered 
eradicatable because of its cccDNA form. However,  eradication will be  attempted by studies  that 
combine  pegylated  IFN-  and  other  investigational  IFN  formulations  with  the  two  most  potent 
NRTIs—ETV and TDF. 
The first two small molecule HCV inhibitors may be licensed in 2011 and many more are likely to 
follow in the next decade. The introduction of new inhibitors will increase the frequency of virological 
cures  and  reduce  HCV  morbidity  and  mortality.  It  will  also  lead  to  widespread  acquired  drug 
resistance  among  the  patients  who  do  not  achieve  sustained  virologic  response.  However,  as  the 
number of licensed new non-cross-resistant inhibitors increases, virological failure will decrease in 
frequency, salvage regimens will be available for patients with resistance to the first generations of 
small molecule inhibitors, and IFN-sparing regimens will be increasingly used. 
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